BNP Paribas Financial Markets Purchases 171,928 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

BNP Paribas Financial Markets boosted its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 1,251.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 185,661 shares of the company’s stock after purchasing an additional 171,928 shares during the period. BNP Paribas Financial Markets’ holdings in Axsome Therapeutics were worth $15,709,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Boxer Capital Management LLC bought a new position in Axsome Therapeutics during the 4th quarter worth $39,767,000. Norges Bank bought a new position in shares of Axsome Therapeutics during the fourth quarter worth about $34,100,000. Principal Financial Group Inc. lifted its stake in shares of Axsome Therapeutics by 6,002.7% in the fourth quarter. Principal Financial Group Inc. now owns 207,065 shares of the company’s stock worth $17,520,000 after acquiring an additional 203,672 shares during the period. Raymond James Financial Inc. bought a new stake in Axsome Therapeutics in the fourth quarter valued at approximately $14,771,000. Finally, Tri Locum Partners LP increased its position in Axsome Therapeutics by 172.3% during the 4th quarter. Tri Locum Partners LP now owns 249,769 shares of the company’s stock valued at $21,133,000 after purchasing an additional 158,048 shares during the period. 81.49% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CFO Nick Pizzie sold 3,000 shares of the firm’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the transaction, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 22.30% of the company’s stock.

Axsome Therapeutics Trading Down 1.0 %

AXSM opened at $107.76 on Friday. Axsome Therapeutics, Inc. has a fifty-two week low of $64.11 and a fifty-two week high of $139.13. The firm has a market capitalization of $5.31 billion, a PE ratio of -17.99 and a beta of 0.46. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. The company’s 50-day moving average is $112.01 and its 200 day moving average is $104.59.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The company had revenue of $118.77 million for the quarter, compared to analyst estimates of $117.83 million. As a group, research analysts predict that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

AXSM has been the topic of a number of recent analyst reports. Leerink Partners boosted their price target on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday, February 10th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Axsome Therapeutics in a research report on Tuesday, February 11th. They set a “buy” rating and a $176.00 price target on the stock. William Blair reissued an “outperform” rating on shares of Axsome Therapeutics in a research report on Tuesday, February 18th. HC Wainwright cut their target price on Axsome Therapeutics from $200.00 to $180.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Jefferies Financial Group initiated coverage on Axsome Therapeutics in a report on Monday, April 7th. They issued a “buy” rating and a $200.00 target price for the company. One analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $172.14.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.